Year end report January – December 2016 Stockholm,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
37
Year end report January – December 2016

Stockholm, 2017-02-24 08:00 CET (GLOBE NEWSWIRE) -- Preparations for the Phase III program with PledOx ®

January – December summary

·       Net result for the year amounted to KSEK -38 223 (-43 836)  

·       Cash equivalents at the end of the period amounted to KSEK 393 998 (50 360)  

·       Cash flow from operating activities amounted to KSEK -36 115 (-51 153)

·       Result per share amounted to SEK -1.3 (-1.5)

Fourth quarter summary

·       Net result for the quarter amounted to KSEK -11 462 (-8 794)  

·       Cash equivalents at the end of the quarter amounted to KSEK 393 998 (50 360)  

·       Cash flow from operating activities amounted to KSEK -9 344 (-8 953)

·       Result per share amounted to SEK -0.3 (-0.3)

Significant events during the year

·       PledPharma completed a guaranteed rights issue of SEK 406 million in order to take         PledOx ® into phase lll

·       PledPharma conducted a constructive meeting with the European Medicines Agency         (EMA)

·       Follow-up data indicates that PledOx ® does not negatively interfere with the anti-cancer         effect of chemotherapy

·       PledPharma presented the Phase IIb PLIANT study data at the American Society of         Clinical Oncology (ASCO) cancer meeting

Significant events after the end of the period  

·       Gunilla Osswald and Elisabeth Svanberg were elected to the Board of Directors. Håkan         Åström and Sten Nilsson will remain on the board.

CEO comment

In 2016 we decided to develop our main product, PledOx ® , towards an application for market registration. This means that we will start pivotal clinical trials, i.e. phase III trials in patients with colorectal cancer during this year. The results from these studies will form the basis for a new drug application (NDA) to the Food and Drug Administration (“FDA”) in the US and for a marketing authorization application (MAA) to the European Medicines Agency (“EMA”) in Europe and as a base for discussions with potential partners. To finance the phase III studies up to top-line results we conducted a new rights issue during the fall.

The results from the Phase IIb study PLIANT has been met with great interest by both clinicians and potential partners. The results were presented in June at the American Society of Clinical Oncology (ASCO), by the study's lead investigator Professor Bengt Glimelius. The follow-up data presented during the year confirms that PledOx ® provides a clinically meaningful reduction of neuropathy compared with the placebo group. Long-term follow-up also showed that PledOx ® has no apparent negative impact on the anti-cancer effect of the chemotherapy.

During the year, we also had a constructive discussion with EMA regarding the continued clinical development of PledOx ® where we received confirmation that the next development stage for PledOx ® is Phase III.  Several potential partners have, however, expressed a wish for additional studies, with patient-reported neuropathy as the primary endpoint, before they are ready for further business discussions. PledPharma has therefore decided to move forward into clinical development by ourselves and thereby create added value in the company.

Since last autumn, there are a series of ongoing activities in preparation for the start of the Phase III studies – that among other things include design of the studies, regulatory preparations and manufacturing.

The previous studies with PledOx ® were performed in patients with metastatic colorectal cancer but as we move into Phase III we will, in addition to metastatic colorectal cancer patients, also include patients treated adjuvantly for colorectal cancer. These patients have great potential to be cured from their cancer. PledOx ® aims to prevent these patients from receiving chronic and debilitating chemotherapy induced nerve injury.

In February this year Gunilla Osswald and Elisabeth Svanberg were elected as new board members to strengthen the expertise in phase III clinical development. Gunilla (PhD in Biopharmaceutics and Pharmacokinetics) has extensive experience in preclinical and clinical drug development, in big pharma and smaller biotech companies and is the CEO at BioArctic AB. Elisabeth (MD, PhD and associate professor of surgery) has extensive experience from leading positions at e.g. Bristol-Myers Squibb and Janssen Pharmaceuticals and is the Chief Development Officer at Ixaltis SA.

In 2016, we furthermore worked on the preparations for the start of a proof of principle study with Aladote ® - a drug candidate with the potential to prevent liver damage in connection with overdosing of paracetamol/acetaminophen. The study aims to identify the possibility to add Aladote ® to the existing treatment for acetaminophen poisoning.

In 2017, when PledPharma moves into Phase III with PledOx ® and furthermore takes Aladote ® into a proof of principle study, this means that PledPharma will have two potential first-in-class drugs in clinical development. We are confident that this will create significant value for our shareholders.

Jacques Näsström , CEO, PledPharma AB (publ)

For more information, please contact :

Jacques Näsström, CEO, phone: +46 737 130 979

Michaela Gertz, CFO, phone: +46 709 26 17 75

About PledPharma

PledPharma develops new drugs that protect the body against oxidative stress – a potentially debilitating and sometimes life-threatening condition that can be caused by chemotherapy treatment and following acetaminophen (paracetamol) overdose. The company's most advanced project PledOx ® reduces nerve damage associated with chemotherapy. A phase IIb study has been conducted and will serve as the basis for the continued phase III development. The drug candidate Aladote ® is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning.

PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser ( tel +46 8 463 80 00) . For more information, see www.pledpharma.se

This information is information that PledPharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on February 24 2017

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 29

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 62

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 66

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 187

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 34

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 309

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 431

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading

Top 5 Most Recently Viewed Articles

Kennedy Funding Secures $2.85M Loan for Innovative Project

Updated Category News Views 187

Kennedy Funding Closes Major Land Loan for Development Leading private lender, Kennedy Funding, has successfully finalized a significant loan amounting to $2.85 million. This financing supports an exciting mixed-use development project that aims to enhance urban living through the addition of residential units and commercial spaces. Details of the Loan Agreement Secured...

Continue Reading
Expert Opinions on Tesla's Recent Vehicle Pricing Strategy

Updated Category News Views 340

Insightful Perspectives on Tesla's Pricing Changes In the dynamic world of electric vehicles, significant voices like Ross Gerber and Gary Black are raising concerns about Tesla Inc. (NASDAQ: TSLA) and its latest pricing strategy for its affordable Model Y and Model 3 trims. These experts have directed their criticism at Tesla following the company's decision to introduce...

Continue Reading
Analyzing Progress and Challenges in America's New Era

Updated Category News Views 259

Progress and Prosperity in America's New Era The past few months have been quite pivotal for the United States as tremendous advancements unfold under the current administration. The focus this week centers around the concept of progress, showcasing the concrete steps made toward economic stability and increased job opportunities. These developments draw attention to the...

Continue Reading
Lithia & Driveway Anticipates Strong Q1 2025 Earnings Report

Updated Category News Views 240

Lithia & Driveway Anticipates Strong Q1 2025 Earnings Report Lithia & Driveway (NYSE: LAD) is preparing to unveil its first quarter financial results for 2025. The company has announced that these results will be available before the market opens, allowing stakeholders and investors to evaluate the performance of the automotive retailer. Key Date for Earnings Release The...

Continue Reading
Hargreave Hale VCT's Recent Share Purchase Explained

Updated Category News Views 118

Correction on Share Purchase Announcement There has been a clarification regarding a previous announcement from Hargreave Hale AIM VCT PLC concerning a recent transaction in their own shares. Initially made public with an incorrect headline, the announcement aims to ensure all shareholders are accurately informed about the company's activities. Details of Share Purchase...

Continue Reading